公司资料
Cullinan Therapeutics, Inc. 股价、新闻与催化剂
- 股票代码:
- CGEM
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
21.68 USD (+1.40%)
收盘价
最后更新: 2026年8月21日
943M USD
市值
股价为何变动
As of Aug 21, 2026, CGEM closed up 1.40% at $21.68. No new same-company headline was identified in the current news window.
公司概览
Autoimmune and Oncology Therapeutics
Cullinan Therapeutics develops targeted therapies and immune-cell engagers across autoimmune disease and cancer.
CLN-978
CLN-978 is a compact CD19-directed T-cell engager designed to deplete B cells. It is being studied in systemic lupus erythematosus and rheumatoid arthritis, including multi-dose evaluation.
Zipalertinib
Zipalertinib is an oral EGFR inhibitor under FDA review for previously treated EGFR exon 20 insertion-positive non-small cell lung cancer.
Velinotamig
Velinotamig is a BCMA-directed T-cell engager in clinical development for multiple myeloma.
未来催化剂
- Initial CLN-978 data in lupus and rheumatoid arthritis at EULAR 2026.
- Multi-dose rheumatoid-arthritis data for CLN-978 in the third quarter of 2026.
- Additional clinical data for velinotamig during 2026.
- PDUFA target action date for zipalertinib on February 27, 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。